Impact de la convection
|
|
- Ashley Stewart
- 6 years ago
- Views:
Transcription
1 Dysfonction Endothéliale, et toxines urémiques des patients dialysés Impact de la convection Ziad A. Massy Ambroise Paré Hospital, University Hospitals Paris Ile de France West, UVSQ, Boulogne Billancourt (Paris), France And INSERM U-1018, CESP, Villejuif(Paris), France
2 Angiogenèse Fonctions endothéliales Métabolisme Perméabilité vasculaire NO H2S PGI2 Endothéline TXA2 PGH2 Tonus vasculaire Hémostase TM Glycocalyx T-PA TFPI PGI2 vwf TF TXA2 PAI-1 Cellule endothéliale Trafic leucocytaire Inflammation ICAM1, VCAM, E-Selectin, MCP1 Prolifération des cellules musculaires lisses
3
4 Cause-specific Deaths in CTT and 4D Baigent, Landray, Wheeler, Sem Dial 2007;20: Non-vascular CHD Other heart disease Stroke n=90,056 n=1,255 CTT General Population 4D Hemodialysis CTT - Cholesterol Treatment Trialists Lancet 2005;366: D Study group N Engl J Med 2005: 353;
5 Systolic aortic expansion rate (ESAO)
6 * * * * * * * * Left ventricular mass (LV mass), Isovolumic relaxation time (IVRT), Tei index and Systolic aortic expansion rate (ESAO)
7 CKD Other varaibles MORTALITY PWV (Temmar et al. J Hypertens 2009)
8 Cai et al. JASN 2014
9 Cai et al. JASN 2014
10 Drueke and Massy Nat Rev Nephrol 2010;6(12):723
11 Uremic Toxins and Endothelium Dysfunction Chronic Kidney Disease Uremic Toxins (or Toxicities) CKD Progression Endothelium Dysfunction
12 Phosphate PTH FGF23 Cardiovascular Disease (Endothelium dysfunction, LVH ) Cardiovascular Calcification All-cause and Cardiovascular Mortality
13 Male Apo E KO mice Ellam et al. ATVB 2011; 31:1988
14 11 young healthy men Shuto et al. JASN 2009,20:1504
15 Gross et al. Circ J 2014
16 Six et al. Cardiovasc Res 2012,96:130
17 Maizel et al. KI 2013; Apr 17 [Epub ahead of print]
18 Finch et al. KI 2013; 84:
19 Gross et al. Circ J 2014
20 Gross et al. Circ J 2014
21 Zoccali et al. JASN 2011
22 CKD Other Factors IL6 FGF23 PWV (J Hypertens 2009) MORTALITY B2M Myoglobin? AGEs? Calcification (J Hypertens 2009)
23 Evidence of Intestinal Barrier Dysfunction in CKD Anders et al. KI 2012
24 Barreto et al, CJASN 2010 *: p < 0.05 vs. IRC stade 2, 3 et 5D : p < 0.05 versus IRC stade 2,3,4 et 5D
25 Aronov et al. JASN 2011
26 Effects of p-cresyl sulfate on vasc. reactivity and remodeling Myosin phosphatase target subunit 1 (MYPT1) Gross P et al. J Cell Physiol 2015;230:
27 Effects of Indoxyl sulfate (IS) and 3 acetic acid (IAA) on endothelial cells COX2 IS AhR F3,PTGS2 CYP1A1,CYP1A2 Inflammation Coagulation IAA P38 MAPK NF-KB TF NF-KB Endothelial Cell Dou et al. Kidney Int. 2004;65:442-51; and Gondouin et al. Kidney Int. 2013;84:733-44
28 Rossi et al. Arch Med Res 2014;45:309
29 CKD Other Factors Free P-cresylsulfate (NDT 2009) PWV (J Hypertens 2009) MORTALITY Total or Free Indoxylsulfate (CJASN 2009) Calcification (J Hypertens 2009)
30 Indole 3 acetic acid and outcomes 120 CKD patients Dou et al. JASN 2014
31
32 Stinghen et al. JASN 2015; [Epub ahead of print]
33 FMD (% change B.A. diam) FMD (% change B.A. diam) Circulating MPs (per ul) Circulating MPs and Endothelial Function (End-Stage Renal Failure ) Endothelial MPs ESRF * Platelet MPs ESRF * Healthy Patients Healthy Patients 0 0 Amabile et al., JASN 2005
34 Survivorship Pronostic value of plasma Endothelial MP end-stage renal disease All-cause mortality Cardiovascular mortality P = P < P = 0.02 P < P = =9.62 P < =18.5 P < Follow-up (months) Follow-up (months) 1 st tertile EMP 2 nd tertile EMP 3 rd tertile EMP Amabile et al. Nephr. Dial. Transpl. 2011, in press
35 Therapeutic Options RAS inhibition Statins Antioxidants Activator NrF2 Dialysis techniques (HDF) Intestinal absorption
36 Bellien et al. NDT 2014
37 Bellien et al. NDT 2014
38 Bellien et al. NDT 2014
39 Ariza et al. Blood Purif 2013
40 Ohtake et al. Ther Aphertesis Dial 2012
41
42 Krieter et al. NDT 2010;25:212
43 Esquivias-Motta et al, HDF and reinfusion Art Org 2016
44 The Gut: The Forgotten Organ in Uremia Schepers et al. Blood Purif 2010
45 Vlassara et al. Kidney Int 2013
46 AST 120 AST120 = oral adsorbant microspheres made from porous carbon material. Clinically used in Japan since 1991 Niwa et al. KI 1997
47 Six et al. Atherosclerosis 2015
48 Six et al. Atherosclerosis 2015
49 AST-120 AND SERUM INDOXYL SULFATE Schulman G. et al, AJKD, 47: ; 2006
50 AST-120 IMPROVES OUTCOME OF DIALYSIS PATIENTS Ueda et al, Ren Fail, 30, , 2008
51 AST 120 : interventional study EPPIC study design : international study No CV endpoint, and no serum Indoxyl sulphate determination Initiation of dialysis Kidney transplantation Doubling of serum creatinine Schulman AJKD 2006 Schulman Poster ASN congress 2012
52 AST 120 : interventional study EPPIC study design : international study No CV endpoint, and no serum Indoxyl sulphate determination Schulman JASN 2014
53 Take Home Messages Uremia and the uremic syndrome are the consequence of the retention of more molecules than urea alone Accumulation of uremic toxins favours the development of non-atherosclerotic (arteriosclerosis via endothelial dysfunction) early on, initially even in the absence of atherosclerosis Convective strategies removing middle molecules seem to have survival advantage but studies may be skewed Classical removal strategies have not much impact on protein bound solute removal Concentration may be influenced by affecting their intestinal absorption and/or by conceptual changes in dialysis treatment
UREMIC TOXINS / MICROBIOME
UREMIC TOXINS / MICROBIOME R Vanholder University Hospital, Gent, Belgium COMPLEX PATHO-PHYSIOLOGY Ikizler et al, KI, 84: 1096-1107; 2013 2 2 UREMIC TOXINS NUTRITION 3 3 THE IMPACT OF NUTRITION ON THE
More informationArterial Pressure in CKD5 - ESRD Population Gérard M. London
Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black
More informationClassification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy
Classification of Endothelial Dysfunction Stefano Taddei Department of Internal Medicine University of Pisa, Italy Pathogenesis of atherosclerosis from endothelial dysfunction to clinical disease endothelial
More informationHDx THERAPY. Enabled by. Making possible personal.
HDx THERAPY Enabled by Making possible personal. THE NEXT HORIZON IN DIALYSIS IS CLOSER THAN YOU THINK PHOSPHATE UREA HDx BY THERANOVA EXPANDS YOUR RENAL POSSIBILITIES The new HDx therapy (expanded HD)
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationStructural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak
Structural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak Kerstin Amann Nephropathology, Dept. of Pathology, University of Erlangen-Nürnberg Krankenhausstr. 8-10 91054
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationLDL cholesterol in CKD to treat or not to treat?
http://www.kidney-international.org & 2013 International Society of Nephrology review LDL cholesterol in CKD to treat or not to treat? Ziad A. Massy 1 and Dick de Zeeuw 2 1 Division of Nephrology, Ambroise
More informationUremic Cardiomyopathy with a focus on the role of α-klotho and FGF23
Uremic Cardiomyopathy with a focus on the role of α-klotho and FGF23 Marc G Vervloet, MD, PhD, FERA VU university medical center Amsterdam, The Netherlands Disclosures Scientific support AbbVie, Amgen,
More informationEffective Treatment Strategies to Delay the Progression of Renal Disease in CKD
Effective Treatment Strategies to Delay the Progression of Renal Disease in CKD Csaba P Kovesdy, MD FASN Memphis VA Medical Center, Memphis TN University of Tennessee, Memphis TN Vitamin D Metabolic acidosis
More informationAssessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France
Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France The causes of Cardiovascular Diseases in CKD Systolic BP;
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationHEMODIAFILTRATION. R Vanholder University Hospital, Gent, Belgium Universitair Ziekenhuis Gent
HEMODIAFILTRATION R Vanholder University Hospital, Gent, Belgium UREMIC SOLUTES LISTED Vanholder et al, KI, 63:1934-1943; 2003 2 2 UREMIC SOLUTES LISTED Vanholder et al, KI, 63:1934-1943; 2003 3 3 UREMIC
More informationStefanos K. Roumeliotis. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Stefanos K.
Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece Passive, degenerative accumulation process of Ca ++ /P +++ without treatment options Active, complex, condition:
More informationIpovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano
Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (
More informationProf. Michel Jadoul Cliniques universitaires St-Luc Université Catholique de Louvain Brussels, Belgium. Slide 1
Phosphate and cardiovascular disease beyond CKD: is phosphate a new cholesterol? Michel Jadoul, Brussels, Belgium Chairs: Pablo Urena Torres, Saint-Ouen, France Carmine Zoccali, Reggio Calabria, Italy
More informationHaemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health
Haemodiafiltration - the case against Prof Peter G Kerr Professor/Director of Nephrology Monash Health Know your opposition.. Haemodiafiltration NB: pre or post-dilution What is HDF how is it different
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationProf. Isabelle Six INSERM Unit 1088 Jules Verne University of Picardie Amiens, France. Slide 1. Slide 2
Effects of phosphate on vascular function New insights Isabelle Six, Amiens, France Chairs: Griet Glorieux, Ghent, Belgium Alberto Ortiz, Madrid, Spain Prof. Isabelle Six INSERM Unit 1088 Jules Verne University
More informationLa relation dialyse et nutrition
Nutrition en dialyse : controverses La relation dialyse et nutrition Charles Chazot, MD NephroCare Tassin-Charcot Sainte Foy Les Lyon, France HEMO study lessons (1) Dose Body weight flux Rocco, Kidney
More informationManagement of anemia in CKD. Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan
Management of anemia in CKD Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan Shiga toxin Kiyoshi Shiga 1871-1957 Shiga toxin binds to
More informationPathophysiology of Vascular Function in CKD. INSERM U970 Hôpital Européen Georges Pompidou Paris
Pathophysiology of Vascular Function in CKD Gérard M. London INSERM U970 Hôpital Européen Georges Pompidou Paris Arterial Pathophysiology and Cardiovascular Diseases in CKD Systolic BP; Diastolic BP Arteriosclerosis
More informationThe Study of Endothelial Function in CKD and ESRD
The Study of Endothelial Function in CKD and ESRD Endothelial Diversity in the Human Body Aird WC. Circ Res 2007 Endothelial Diversity in the Human Body The endothelium should be viewed for what it is:
More informationCardiovascular Biomarkers in CKD and in ESRD. Alberto Ortiz, MD, PhD IIS-Fundacion Jimenez Diaz Madrid, Spain
Cardiovascular Biomarkers in CKD and in ESRD Alberto Ortiz, MD, PhD IIS-Fundacion Jimenez Diaz Madrid, Spain Accelerated aging in ESRD CKD patients: CVD mortality USRDS: Levey et al. Am J Kidney Dis 1998
More informationEnd stage renal disease and Protein Energy wasting
End stage renal disease and Protein Energy wasting Dr Goh Heong Keong MBBS,MRCP(UK) www.passpaces.com/kidney.htm Introduction Chronic kidney disease- increasing health burden in many countries. The estimated
More informationThe New Cardiorenal Syndrome
The New Cardiorenal Syndrome Peter Sawaya, MD, FACP, FASN Professor of Medicine Fellowship Program Director University of Kentucky The Old Cardiorenal Syndrome Heart Perfusion Na Retention Kidney What
More informationDietary practices in patients with chronic kidney disease not yet on maintenance dialysis: What are the relevant components?
Dietary practices in patients with chronic kidney disease not yet on maintenance dialysis: What are the relevant components? 3 rd International Conference of European Renal Nutrition Working Group of ERA-EDTA
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationD Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis
Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis,
More informationTargeting vascular damage (stiffness, calcifications) in CKD: beyond blood pressure
Targeting vascular damage (stiffness, calcifications) in CKD: beyond blood pressure Should we still measure BP in dialysis? Clinical Problems with cuff BP Case #1: Variances in Cuff BP vs. Central BP 140/80
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationCardiorenal Syndrome
Cardiorenal Syndrome Peenida Skulratanasak, M.D. Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University Definition of Cardiorenal syndrome (CRS) Structural
More informationNicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD
Biomarker der kardio-renalen Achse Mannheim, 20. Januar 2017 Nicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD Prof. Dr. med. Thomas Bernd Dschietzig Immundiagnostik AG, Bensheim Med. Klinik m.
More informationKlotho: renal and extra-renal effects
Klotho: renal and extra-renal effects Juan F. Navarro-González, MD, PhD, FASN Nephrology Service and Research Division University Hospital Nuestra Señora de Candalaria Santa Cruz de Tenerife. Spain Klotho:
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationEffect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
Clinical Practice: Second Opinion Received: July 29, 2016 Accepted after revision: November 22, 2016 Published online: December 14, 2016 Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
More informationHemodialysis: slightly beyond basics Dialysate calcium and magnesium concentrations
Dialysate calcium and magnesium concentrations Stefan Farese Department of Nephrology Bürgerspital Solothurn 04.12.2013 Dialysate calcium and magnesium concentrations Do we know the optimal concentrations?
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationEffects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease
bs_bs_banner Therapeutic Apheresis and Dialysis 2015; 19(5):436 440 doi: 10.1111/1744-9987.12307 Review Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationAttivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi
Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi Mario Cozzolino, MD, PhD, FERA Dipartimento di Scienze della Salute Università di Milano UO Nefrologia e Dialisi Laboratorio
More informationSympathetic nervous system and NO in CKD. Francesca Mallamaci
Sympathetic nervous system and NO in CKD Francesca Mallamaci Go AS, New Engl J Med. 351: 1296; 24 1.12.295 individuals, follow up 2.8 yea risk factors peculiar to CKD Old age Relative Risk (fully independent)
More informationAchieving Equilibrium in ESRD Patients
Achieving Equilibrium in ESRD Patients -Marc Richards MD -South Florida Kidney Disease and HTN Specialists -Chief of Medicine, BRRH -BRRH Grand Rounds: April 18 th, 2017 Outline Dialysis prescription Adequacy
More informationNovel Markers of Arterial Dysfunction
혈관연구회창립심포지움, 3 월 3 일, 2005 Novel Markers of Arterial Dysfunction Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon Medical School Incheon, Korea Atherosclerosis: A progressive process PHASE I: Initiation
More informationINSPIRED BY LIFE B. BRAUN DIALYZERS
INSPIRED BY LIFE B. BRAUN DIALYZERS OUR COMMITMENT. FOR LIFE. The Diacap Pro and xevonta dialyzers offer a broad range of high-quality dialyzers for individual treatment needs. It began in 1839, inspired
More informationMicroparticles- Signaling in Atherothrombosis Agneta Siegbahn, MD, PhD, FESC Professor in Coagulation Science
Microparticles- Signaling in Atherothrombosis Agneta Siegbahn, MD, PhD, FESC Professor in Coagulation Science Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Uppsala,
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationPlasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients
http://www.kidney-international.org & 2012 International Society of Nephrology Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients Sophie Liabeuf 1,2,3, Aurélie Lenglet
More informationDeclaration of conflict of interest
Declaration of conflict of interest Inhibitors of vascular calcification what have we learned from animal models Ralf Westenfeld Department of Cardiology Heinrich-Heine-University Düsseldorf Do you know
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationAllopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease
Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of
More informationCOGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E
COGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E Attention Problem Solving Language Cognitive Domains Decision Making Memory Reasoning The Cardiovascular Health Cognition Study shows higher S
More informationCardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease
Poesen et al. BMC Nephrology 2014, 15:87 RESEARCH ARTICLE Open Access Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease Ruben Poesen 1, Liesbeth Viaene
More informationHans Strijdom SA Heart Meeting November 2017
Hans Strijdom SA Heart Meeting November 2017 HIV-infection and ART, but not high sensitivity CRP, are associated with markers of vascular function: Results from the Western Cape cohort of the EndoAfrica
More informationDECLARATION OF CONFLICT OF INTEREST. No conflicts of interest
DECLARATION OF CONFLICT OF INTEREST No conflicts of interest University Heart Centre Tübingen Angiogenic actions of platelets Meinrad Gawaz, MD, FESC Tübingen, Germany ESC 2011 Paris GPIb GPIb GPVI TxA2
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationHyperphosphatemia is associated with a
TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular
More informationHEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI
HEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI high-flux Hemodiafiltration (HDF) Combination of two dialysis techniques, hemodialysis and hemofiltration:
More informationBONE AND MINERAL METABOLISM in the PD PATIENT
BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationModern Medical Laboratory Journal - ISSN X
Original Article Mod Med Lab. 2017; 1(1): 17-17 22 Modern Medical Laboratory Journal - ISSN 2371-770X An Investigation of the Relationship between Beta-2 Microglobulin (β2m) and Inflammatory Factors (Serum
More informationHEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS 1.0 PRACTICE CONSIDERATIONS 2.0 CURRENT LITERATURE REVIEW
HEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS This document was prepared at the request of the BC Hemodialysis Committee to provide a brief overview of the literature and to identify
More informationImpact of L-carnitine Pretreatment on Intravenous Iron Administration-induced Oxidative Stress and Inflammatory Response in Patients with CKD
Impact of L-carnitine Pretreatment on Intravenous Iron Administration-induced Oxidative Stress and Inflammatory Response in Patients with CKD Dr. Zaher Armaly Nephrology Department Nazareth EMMS Hospital
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationNew developments in dialysis membranes for chronic HD patients. What will bring the near future?
New developments in dialysis membranes for chronic HD patients. What will bring the near future? Pr L. JUILLARD Département de Néphrologie, H. E. Herriot, Hospices Civils de Lyon, Lyon. INSERM U1060, Carmen,
More informationΛΟΙΜΩΞΗ HIV. Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική
ΛΟΙΜΩΞΗ HIV Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική Κλινική, Νοσοκομείο «Αττικόν» Infection Acute Myocardial Infarction p er 100,000 HIV/AIDS discharg es 800 700 600 500 400 300 200
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationKDIGO. CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke
CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke Unité 1088 de l Inserm UFR de Médecine et de Pharmacie Jules Verne University of Picardie Amiens, France Poten2al conflicts of interest Research support:
More informationKDIGO LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE
LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE Dr. Christopher T Chan Director Division of Nephrology University Health Network Professor of Medicine University of Toronto Disclosure
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationCardiovascular Implications of Proteinuria
Cardiovascular Implications of Proteinuria B. S. Kasinath, MD University of Texas Health Science Center South Texas Veterans Health Care System San Antonio Objectives Mechanisms of albumin handling by
More informationAthérosclérose - Plaque Physiopathologie, Evaluation
Athérosclérose - Plaque Physiopathologie, Evaluation Dr Philippe GAROT Institut Cardiovasculaire Paris Sud MASSY-QUINCY www.rcf-icps.com Mécanisme cellulaire Constitution de la plaque d athérome Monocytes
More informationCardiovascular disease and diabetes Vascular harmony
Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics
More informationNovel technologies for blood purification Prof. Dr. Dimitrios Stamatialis
Novel technologies for blood purification Prof. Dr. Dimitrios Stamatialis Biomaterials Science and Technology, MIRA institute, University of Twente 1 BST group MIRA: Technology for regeneration 5 My
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationPr Dominique Prié, Université Paris Descartes, Faculté de Médecine,
KLOTHO: CLINICAL ASPECTS Pr Dominique Prié, Université Paris Descartes, Faculté de Médecine, Institut Necker-Enfants Malades INSERM Service des Explorations Fonctionnelles Hôpital Necker-Enfants Malades,
More informationReport and Opinion 2016;8(12)
Prevalence of calcific aortic valve stenosis in haemodialysis patients at AL Hussein University Hospital. Ahmed Alaa Saad 1, Sami H. Nooh 2, Osama A. Khamis 1, Magdy E. Mohamed 1, Mohamed Abdelhafez 1
More informationThe Role of Dialyzers in Cardiac Protection. Prof. Dr. Eng. Jörg Vienken BioSciences, Fresenius Medical Care, Bad Homburg, Germany
The Role of Dialyzers in Cardiac Protection Prof. Dr. Eng. Jörg Vienken BioSciences, Fresenius Medical Care, Bad Homburg, Germany With a Sense for Details! 1999 Peter Vienken, 11 years Prof. Pim Kolff,
More informationHeart Failure with Preserved Ejection Fraction: Mechanisms and Management
Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Jay N. Cohn, M.D. Professor of Medicine Director, Rasmussen Center for Cardiovascular Disease Prevention University of Minnesota
More informationJournal of Infectious Diseases Advance Access published August 25, A Practical Treatment for Patients with Ebola Virus Disease
Journal of Infectious Diseases Advance Access published August 25, 2014 1 A Practical Treatment for Patients with Ebola Virus Disease David S. Fedson Correspondence: David S. Fedson, MD, 57, chemin du
More informationHemolytic uremic syndrome: Investigations and management
Hemolytic uremic syndrome: Investigations and management SAWAI Toshihiro M.D., Ph.D. Department of Pediatrics, Shiga University of Medical Science Otsu, JAPAN AGENDA TMA; Thrombotic micro angiopathy STEC-HUS;
More informationRenal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology
Renal Disease and PK/PD Anjay Rastogi MD PhD Division of Nephrology Drugs and Kidneys Kidney is one of the major organ of drug elimination from the human body Renal disease and dialysis alters the pharmacokinetics
More informationAdipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University
Adipose Tissue as an Endocrine Organ Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University Functions of Adipose Tissue Adipose tissue expresses and secretes a variety of bioactive peptides,
More informationINVITED REVIEW ARTICLE UREMIC TOXICITY OF INDOXYL SULFATE
Nagoya J. Med. Sci. 72. 1 ~ 11, 2010 INVITED REVIEW ARTICLE UREMIC TOXICITY OF INDOXYL SULFATE TOSHIMITSU NIWA Department of Advanced Medicine for Uremia, Nagoya University School of Medicine ABSTRACT
More informationDisclosures. History. Case. Using the peritoneal cavity for dialysis. Background 2/4/2015 ASDIN PD in the Acute Setting- Myth or Reality?
PD in the Acute Setting- Myth or Reality? ASDIN Scientific Meeting February 15, 2015 Disclosures Investigator: BARD, Otsuka, Shire, Gilead Grants: Amgen Consultant: Covidien, Deltanoid No disclosures for
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationYoshie Kanazawa 1,2, Shunsuke Morita 3, Hirofumi Sonoki 3 and Toshiyuki Nakao 1,4*
Kanazawa et al. Renal Replacement Therapy (2016) 2:18 DOI 10.1186/s41100-016-0031-5 RESEARCH Open Access Effects of a novel nutritional formula specially developed for chronic kidney disease patients on
More informationNon Conventional cardiovascular risk factors in CKD
Non Conventional cardiovascular risk factors in CKD Death rates for major cardiovascular diseases have decreased in the United States Cooper, R, Cutler, J, Desvigne-Nickens, P, et al. Circulation 2000;
More informationASDIN 7th Annual Scientific Meeting
Reported incidence 1-20% Loay Salman, MD Assistant Professor of Medicine University of Miami Miller School of Medicine Tordoir et al. J Vasc Endovasc Sur. 2004 Morsy et al. J Surg Res. 1998 Haimov et al.
More informationUpdate on home dialysis
Update on home dialysis dr. Karlien François Nefrologie, UZ Brussel Let s start with the good news on PD! Tx All HD = PD ERA EDTA Annual Report 2014 ...despite we don t do it so often ERA EDTA Annual Report
More information17 th Annual Meeting of JSHDF, Sept 3-4, 2011
17 th Annual Meeting of JSHDF, Sept 3-4, 2011 Sug Kyun Shin 1, JY Moon 2, SW Han 3, DH Yang 4, SH Lee 2, HC Park 5, JK Kim 6 and YI Jo 7 1 Nephrology, NHIC Ilsan Hospital, 2 Kyunghee University Hospital
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationWORKSHOP #6: LA DISFUNZIONE VENTRICOLARE OCCULTA E NON: - Nella Patologia renale. Luigi Tarantini Osp. San Martino - (Belluno)
WORKSHOP #6: LA DISFUNZIONE VENTRICOLARE OCCULTA E NON: - Nella Patologia renale Luigi Tarantini Osp. San Martino - (Belluno) Il paziente con Malattia Renale Cronica è il paziente ad alto rischio CV (1)
More information